EUVIMEDEUVIMED entdecken
Multizentrische Studie

The characteristics and prognostic analysis of therapy-related acute myeloid leukemia patients in China

Feifei Tang, Yunqi Wang, Yu Zhang, Hongyu Zhang, Jinhai Ren, Pengcheng He, Yajing Xu, Hua Yan, Yongqian Jia, Liping Dou, Tao Wu, Zhi Guo und 8 weitere

Science China Life Sciences · 2026

DOI: 10.1007/s11427-024-2974-3 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Science China Life Sciences, 2026. Verfasst von Feifei Tang und 19 weiteren Autor:innen. Beteiligte Einrichtung: Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Ke…. Hauptthemen laut MEDLINE: Leukemia, Myeloid, Acute. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 49 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

We aimed to firstly explore characteristics and prognostic factors of therapy-related acute myeloid leukemia (t-AML) in multi-center samples in China. We analyzed 228 t-AML patients from 14 centers across China. The median age at t-AML diagnosis was 52 years (range, 1.3-89 years). The median latency interval was 45.8 months (19.2-142.8 months). Next generation sequencing (NGS) results were available in 150 (65.8%) patients. The overall survival (OS) and disease-free survival rates of all t-AML were 58.3% and 63.7%, respectively. In t-AML patients, NPM1 mutation (85.0% vs. 54.4%, P=0.01), core binding factor (CBF) (RUNX1/RUNX1T1 and CBFβ/MYH11) (70.7% vs. 55.1%, P=0.03), and allogeneic hematopoietic stem cell transplantation (allo-HSCT) (86.0% vs. 67.9%, P=0.02) were associated with significantly better OS, while the 2022 ELN intermediate-adverse risk group had worse OS than the favorable group (55.9% vs. 73.1%, P=0.02). In multivariable analyses, NPM1 mutation, CBF t-AML, primary tumor remission, WBC count ⩽15×109 L-1, CRc after one course and allo-HSCT were associated with favorable OS. Regarding NGS molecular analysis, in addition to the positive effects of NPM1 on OS, our study identified TP53 mutation as a risk factor associated with poor OS (40.0% vs. 66.6%, P=0.03, HR=2.64). We developed a prognostic scoring system including clinical and molecular profiles termed NTCTH (NPM1 (HR=0.16), TP53 (HR=3.45), CBF t-AML (HR=0.09), first course intensive induction Therapy regime (HR=0.24), and allo-HSCT (HR=0.36)) in patients who performed NGS. Our study first demonstrated prognostic factors of t-AML in large samples from multiple centers in China and found that NPM1 and CBF t-AML were associated with superior OS, and TP53 was associated with inferior OS.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Leukemia, Myeloid, AcuteHumansNucleophosminMiddle AgedAdultChinaPrognosisMaleFemaleAgedAdolescentYoung AdultMutationHematopoietic Stem Cell TransplantationAged, 80 and overChildChild, PreschoolInfantNuclear ProteinsHigh-Throughput Nucleotide SequencingDisease-Free Survival

Stichwörter der Autor:innen

next generation sequencingprognostic analysistherapy-related acute myeloid leukemia

Substanzen

NucleophosminNPM1 protein, humanNuclear Proteins

Autor:innen und Institutionen

  • Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Peking Univer…
  • Nanfang Hospital, Southern Medical University, Guangzhou, 510515, China.
  • Peking University Shenzhen Hospital, Shenzhen, 518036, China.
  • Hematology Institute of Hebei Province, Second Hospital of Hebei Medical University, Shijiazhuang, 050000, China.
  • The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, 710061, China.
  • Xiangya Hospital, Central South University, Changsha, 410008, China.

Zitieren

APA

Tang, F., Wang, Y., Zhang, Y., Zhang, H., Ren, J., He, P., Xu, Y., Yan, H., Jia, Y., Dou, L., Wu, T., Guo, Z., Yuan, X., Fang, Y., Wu, X., Jiang, Q., Jiang, H., Xu, L., Zhang, X., & Huang, X. (2026). The characteristics and prognostic analysis of therapy-related acute myeloid leukemia patients in China. Science China Life Sciences. https://doi.org/10.1007/s11427-024-2974-3

Vancouver

Tang F, Wang Y, Zhang Y, Zhang H, Ren J, He P, et al. The characteristics and prognostic analysis of therapy-related acute myeloid leukemia patients in China. Science China Life Sciences. 2026. doi:10.1007/s11427-024-2974-3

BibTeX
@article{Tang2026,
  author = {Tang, Feifei and Wang, Yunqi and Zhang, Yu and Zhang, Hongyu and Ren, Jinhai and He, Pengcheng and Xu, Yajing and Yan, Hua and Jia, Yongqian and Dou, Liping and Wu, Tao and Guo, Zhi and Yuan, Xiaojun and Fang, Yongjun and Wu, Xiaoyan and Jiang, Qian and Jiang, Hao and Xu, Lanping and Zhang, Xiaohui and Huang, Xiaojun},
  title = {The characteristics and prognostic analysis of therapy-related acute myeloid leukemia patients in China},
  journal = {Science China Life Sciences},
  year = {2026},
  doi = {10.1007/s11427-024-2974-3}
}
Kostenlos starten →